Literature DB >> 25293774

CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.

Dominik Schneidawind1, Antonio Pierini1, Maite Alvarez1, Yuqiong Pan1, Jeanette Baker1, Corina Buechele2, Richard H Luong3, Everett H Meyer1, Robert S Negrin1.   

Abstract

Dysregulated donor T cells lead to destruction of host tissues resulting in graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). We investigated the impact of highly purified (>95%) donor CD4(+) invariant natural killer T (iNKT) cells on GVHD in a murine model of allogeneic HCT. We found that low doses of adoptively transferred donor CD4(+) iNKT cells protect from GVHD morbidity and mortality through an expansion of donor CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs). These Tregs express high levels of the Ikaros transcription factor Helios and expand from the Treg pool of the donor graft. Furthermore, CD4(+) iNKT cells preserve T-cell-mediated graft-versus-tumor effects. Our studies reveal new aspects of the cellular interplay between iNKT cells and Tregs in the context of tolerance induction after allogeneic HCT and set the stage for clinical translation.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25293774      PMCID: PMC4239338          DOI: 10.1182/blood-2014-05-576017

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation.

Authors:  Vu H Nguyen; Robert Zeiser; Daniel L Dasilva; Daisy S Chang; Andreas Beilhack; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-11-09       Impact factor: 22.113

2.  Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.

Authors:  Marie-Thérèse Rubio; Lucia Moreira-Teixeira; Emmanuel Bachy; Marie Bouillié; Pierre Milpied; Tereza Coman; Felipe Suarez; Ambroise Marcais; David Sibon; Agnès Buzyn; Sophie Caillat-Zucman; Marina Cavazzana-Calvo; Bruno Varet; Michel Dy; Olivier Hermine; Maria Leite-de-Moraes
Journal:  Blood       Date:  2012-06-22       Impact factor: 22.113

3.  Host-residual invariant NK T cells attenuate graft-versus-host immunity.

Authors:  Kyoko Haraguchi; Tsuyoshi Takahashi; Akihiko Matsumoto; Takashi Asai; Yoshinobu Kanda; Mineo Kurokawa; Seishi Ogawa; Hideaki Oda; Masaru Taniguchi; Hisamaru Hirai; Shigeru Chiba
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

4.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

5.  Induced immune tolerance for kidney transplantation.

Authors:  John D Scandling; Stephan Busque; Judith A Shizuru; Edgar G Engleman; Samuel Strober
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

6.  CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma.

Authors:  Omid Akbari; John L Faul; Elisabeth G Hoyte; Gerald J Berry; Jan Wahlström; Mitchell Kronenberg; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  N Engl J Med       Date:  2006-03-16       Impact factor: 91.245

7.  Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.

Authors:  Joshua Richter; Natalia Neparidze; Lin Zhang; Shiny Nair; Tamara Monesmith; Ranjini Sundaram; Fred Miesowicz; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2012-10-24       Impact factor: 22.113

8.  Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells.

Authors:  Fengshuo Lan; Defu Zeng; Masanori Higuchi; John P Higgins; Samuel Strober
Journal:  Biol Blood Marrow Transplant       Date:  2003-06       Impact factor: 5.742

9.  Methods for detection, isolation and culture of mouse and human invariant NKT cells.

Authors:  Hiroshi Watarai; Ryusuke Nakagawa; Miyuki Omori-Miyake; Nyambayar Dashtsoodol; Masaru Taniguchi
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

10.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Authors:  Matthias Edinger; Yu-An Cao; Michael R Verneris; Michael H Bachmann; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

View more
  49 in total

1.  Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors:  Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

2.  Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

Authors:  Michael A Spinner; Vanessa E Kennedy; John S Tamaresis; Philip W Lavori; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Andrew R Rezvani; Judith A Shizuru; Wen-Kai Weng; Richard T Hoppe; Samuel Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2019-08-27

3.  Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Authors:  Yi-Bin Chen; Yvonne A Efebera; Laura Johnston; Edward D Ball; David Avigan; Lazaros J Lekakis; Carlos R Bachier; Paul Martin; Omar Duramad; Yasuyuki Ishii; Semi Han; Yu-Jin Jung; Dana Lee; Lori Kunkel; Robert S Negrin; Jack D Bui
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-16       Impact factor: 5.742

4.  Pre-transplant donor CD4- invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease.

Authors:  M-T Rubio; M Bouillié; N Bouazza; T Coman; H Trebeden-Nègre; A Gomez; F Suarez; D Sibon; A Brignier; E Paubelle; S Nguyen-Khoc; M Cavazzana; O Lantz; M Mohty; S Urien; O Hermine
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

5.  High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity.

Authors:  Tom Erkers; Bryan J Xie; Laura J Kenyon; Brian Smith; Mary Rieck; Kent P Jensen; Xuhuai Ji; Marina Basina; Samuel Strober; Robert S Negrin; Holden T Maecker; Everett H Meyer
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

6.  Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.

Authors:  Dominik Schneidawind; Jeanette Baker; Antonio Pierini; Corina Buechele; Richard H Luong; Everett H Meyer; Robert S Negrin
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

7.  Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.

Authors:  Abel Trujillo-Ocampo; Hyun-Woo Cho; Amanda C Herrmann; Wilfredo Ruiz-Vazquez; Andrew B Thornton; Hong He; Dan Li; Mariam A Qazilbash; Qing Ma; Steven A Porcelli; Elizabeth J Shpall; Jeffrey Molldrem; Jin S Im
Journal:  Cytotherapy       Date:  2018-07-31       Impact factor: 5.414

8.  TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.

Authors:  Antonio Pierini; William Strober; Caitlin Moffett; Jeanette Baker; Hidekazu Nishikii; Maite Alvarez; Yuqiong Pan; Dominik Schneidawind; Everett Meyer; Robert S Negrin
Journal:  Blood       Date:  2016-06-30       Impact factor: 22.113

9.  Regulatory T Cell Immunotherapy in Immune-Mediated Diseases.

Authors:  Antonio Pierini; Dominik Schneidawind; Hidekazu Nishikii; Robert S Negrin
Journal:  Curr Stem Cell Rep       Date:  2015-09-12

10.  Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation.

Authors:  Koji Kawaguchi; Katsutsugu Umeda; Eitaro Hiejima; Atsushi Iwai; Masamitsu Mikami; Seishiro Nodomi; Satoshi Saida; Itaru Kato; Hidefumi Hiramatsu; Takahiro Yasumi; Ryuta Nishikomori; Tadakazu Kondo; Akifumi Takaori-Kondo; Toshio Heike; Souichi Adachi
Journal:  Int J Hematol       Date:  2018-03-26       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.